Desmopressin Teva B.V.: Uses, Dosage & Side Effects
Synthetic vasopressin analogue for diabetes insipidus, nocturnal enuresis and nocturia
Quick Facts about Desmopressin Teva B.V.
Key Takeaways about Desmopressin Teva B.V.
- Treats central diabetes insipidus: Desmopressin replaces the missing antidiuretic hormone to reduce excessive urination and thirst
- Effective for bedwetting: Approved for primary nocturnal enuresis in children aged 5+ and adults when non-pharmacological measures have failed
- Hyponatraemia is the main risk: Fluid intake must be restricted from 1 hour before to 8 hours after dosing to prevent dangerously low sodium levels
- Multiple formulations available: Available as tablets, oral lyophilisates (melt-on-tongue), nasal spray and injection to suit different patient needs
- Regular monitoring required: Blood sodium levels should be checked before starting, during the first week, and periodically thereafter
What Is Desmopressin Teva B.V. and What Is It Used For?
Desmopressin Teva B.V. is a synthetic version of vasopressin (antidiuretic hormone) that reduces urine production by acting on the kidneys. It is primarily prescribed for central diabetes insipidus, primary nocturnal enuresis (bedwetting) and nocturia in adults with nocturnal polyuria.
Desmopressin is a modified form of the naturally occurring hormone arginine vasopressin (AVP), also known as antidiuretic hormone (ADH). The natural hormone is produced by the hypothalamus and released from the posterior pituitary gland, where it plays a critical role in regulating the body's water balance. In patients with central diabetes insipidus, the body fails to produce sufficient ADH, leading to excessive urination (polyuria) and intense thirst (polydipsia). Desmopressin replaces this missing hormone and effectively controls these symptoms.
What distinguishes desmopressin from natural vasopressin is its enhanced antidiuretic potency and prolonged duration of action. Through structural modifications to the vasopressin molecule, desmopressin has been engineered to have significantly greater selectivity for the V2 receptors found in the renal collecting ducts. This means it concentrates urine efficiently while having minimal effect on blood pressure (V1 receptor activity), making it considerably safer for long-term use than the natural hormone.
The primary clinical indications for Desmopressin Teva B.V. include:
- Central diabetes insipidus: Both diagnostic testing and long-term treatment of insufficient production of ADH by the pituitary gland, resulting in excessive dilute urine output
- Primary nocturnal enuresis: Treatment of bedwetting in children aged 5 years and older and in adults, when non-pharmacological approaches (alarm therapy, fluid restriction) have been insufficient
- Nocturia with nocturnal polyuria: Reduction of nighttime urination in adults who produce excessive urine during sleep, significantly improving sleep quality and daytime functioning
- Renal concentration capacity testing: Diagnostic assessment of how well the kidneys can concentrate urine, helping to differentiate between central and nephrogenic diabetes insipidus
Desmopressin has also been used off-label in certain haematological conditions, including mild haemophilia A and type 1 von Willebrand disease, where it stimulates the release of von Willebrand factor and factor VIII from endothelial storage sites. However, these indications typically require intravenous or subcutaneous administration and are managed by specialist haematologists.
When desmopressin binds to V2 receptors on the basolateral membrane of renal collecting duct cells, it triggers a signalling cascade that inserts aquaporin-2 water channels into the apical membrane. These channels allow water to be reabsorbed from the urine back into the bloodstream, concentrating the urine and reducing its volume. This mechanism is identical to how natural ADH works, but desmopressin achieves a stronger and longer-lasting effect.
What Should You Know Before Taking Desmopressin Teva B.V.?
Before starting desmopressin, your doctor must assess your kidney function, sodium levels and fluid balance. The medication is contraindicated in habitual polydipsia, cardiac insufficiency requiring diuretics, and hyponatraemia. Fluid restriction is essential to prevent water intoxication.
Desmopressin is a powerful antidiuretic medication that requires careful patient selection and monitoring. Before prescribing desmopressin, your healthcare provider will conduct a thorough assessment including blood tests for sodium levels, kidney function tests, and a detailed medical history. Understanding the contraindications, warnings and precautions is essential for safe use of this medication.
Contraindications
You should not take Desmopressin Teva B.V. if any of the following apply:
- Habitual or psychogenic polydipsia: If you drink excessive amounts of fluid habitually (more than 40 ml/kg/24 hours), as this dramatically increases the risk of water intoxication
- Known hyponatraemia: If your blood sodium levels are already low or if you have a history of recurrent hyponatraemia
- Cardiac insufficiency: If you have heart failure or other conditions requiring treatment with diuretic medications
- Moderate to severe renal insufficiency: If your kidney function is significantly impaired (creatinine clearance below 50 ml/min)
- Syndrome of inappropriate ADH secretion (SIADH): If your body already produces excessive amounts of antidiuretic hormone
- Known hypersensitivity: If you have previously had an allergic reaction to desmopressin or any of the excipients in the formulation
Warnings and Precautions
Several important warnings apply when using desmopressin:
The most serious risk of desmopressin therapy is hyponatraemia (low blood sodium). This occurs when excessive water retention dilutes sodium in the blood, potentially causing headache, nausea, vomiting, seizures, and in severe cases, cerebral oedema and death. Fluid intake must be restricted from 1 hour before until 8 hours after each dose. Drink only when truly thirsty and limit intake to small sips.
Additional precautions include:
- Elderly patients: Older adults are at increased risk of hyponatraemia due to age-related changes in kidney function and sodium regulation. Lower starting doses and more frequent monitoring are recommended
- Children: Careful dose titration is required, and parents must be educated about fluid restriction protocols. Treatment should be interrupted during acute illness with fever, vomiting or diarrhoea
- Cardiovascular conditions: Patients with coronary artery disease, hypertension or conditions associated with fluid overload require careful monitoring
- Cystic fibrosis: Patients with cystic fibrosis may be at increased risk of electrolyte imbalances and should be monitored closely
- Acute illness: Treatment should be temporarily discontinued during episodes of fever, gastroenteritis, or any illness affecting fluid balance, as these conditions increase the risk of hyponatraemia
Pregnancy and Breastfeeding
The use of desmopressin during pregnancy and breastfeeding requires careful consideration:
Pregnancy: Limited data from clinical studies and post-marketing experience with desmopressin in pregnant women (primarily those with diabetes insipidus) have not indicated any adverse effects on pregnancy or the health of the foetus or newborn. Animal reproduction studies have not revealed any harmful effects. However, as with all medications during pregnancy, desmopressin should only be used when the potential benefit justifies the potential risk. Pregnant women taking desmopressin require close monitoring of fluid balance and sodium levels, as the physiological changes of pregnancy can alter fluid homeostasis.
Breastfeeding: Following oral administration of 300 mcg desmopressin, the amount excreted in breast milk is considerably less than the amount required to influence diuresis in the nursing infant. Desmopressin is therefore generally considered compatible with breastfeeding, although the prescribing physician should weigh the benefits against any potential risks on a case-by-case basis.
How Does Desmopressin Teva B.V. Interact with Other Drugs?
Desmopressin can interact with several medication classes that affect water balance or sodium levels. Drugs that increase ADH secretion (tricyclic antidepressants, SSRIs, carbamazepine) may enhance its antidiuretic effect and increase hyponatraemia risk, while lithium and demeclocycline may reduce its effectiveness.
Drug interactions with desmopressin are primarily related to its effect on water balance and can be clinically significant. Some medications potentiate the antidiuretic effect (increasing hyponatraemia risk), while others may reduce the effectiveness of desmopressin. Your prescribing physician and pharmacist should be informed of all medications you are taking, including over-the-counter products and herbal supplements.
Major Interactions
The following drug classes have clinically important interactions with desmopressin and may require dose adjustment, enhanced monitoring, or avoidance of combination:
| Drug / Class | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Tricyclic antidepressants (e.g. amitriptyline, imipramine) | Potentiation | Increased antidiuretic effect; higher risk of hyponatraemia | Monitor sodium closely; consider dose reduction |
| SSRIs (e.g. fluoxetine, sertraline, paroxetine) | Potentiation | Enhanced water retention; SSRIs independently cause SIADH | Frequent sodium monitoring; strict fluid restriction |
| Carbamazepine / Oxcarbazepine | Potentiation | Both drugs have intrinsic antidiuretic activity; additive hyponatraemia risk | Monitor sodium; consider alternative anticonvulsant |
| Chlorpromazine | Potentiation | Increases ADH release; augments antidiuretic effect | Enhanced monitoring of sodium and fluid balance |
| NSAIDs (e.g. indomethacin, ibuprofen) | Potentiation | NSAIDs reduce renal prostaglandin synthesis, enhancing water reabsorption | Use with caution; monitor renal function and sodium |
| Loperamide | Potentiation | May increase desmopressin plasma concentration by up to 3-fold | Avoid concurrent use or reduce desmopressin dose |
Drugs That May Reduce Effectiveness
Certain medications can antagonise the antidiuretic effect of desmopressin:
- Lithium: Directly inhibits the renal response to ADH at the collecting duct level, reducing desmopressin's ability to concentrate urine. This is one reason lithium itself causes nephrogenic diabetes insipidus
- Demeclocycline: A tetracycline antibiotic that blocks the action of ADH on renal tubular cells. It is actually used therapeutically to treat SIADH, highlighting its antagonistic effect on desmopressin
- Alcohol: Inhibits ADH release and increases urine production, counteracting the therapeutic effect of desmopressin. Patients should be advised to limit alcohol consumption, especially in the evening
- Glucocorticoids: High-dose corticosteroids can increase free water clearance and may reduce the antidiuretic effect of desmopressin
What Is the Correct Dosage of Desmopressin Teva B.V.?
Desmopressin dosage varies by indication and patient group. For central diabetes insipidus, the typical adult oral dose is 0.1-0.2 mg two to three times daily. For nocturnal enuresis, the starting dose is usually 0.2 mg at bedtime. Dosing must be individually titrated by a physician based on clinical response and sodium monitoring.
Desmopressin dosing is highly individualised and depends on the indication, the formulation being used, the patient's age and weight, and their clinical response. It is critical to note that the different formulations (tablets, oral lyophilisates, nasal spray, injection) are not dose-equivalent and cannot be directly substituted without dose adjustment. Your physician will determine the most appropriate dose and formulation for your specific situation.
Adults
| Indication | Starting Dose | Usual Range | Maximum Dose | Administration |
|---|---|---|---|---|
| Central diabetes insipidus | 0.1 mg three times daily | 0.2-1.2 mg/day in divided doses | 1.2 mg/day | Oral tablets |
| Nocturnal enuresis | 0.2 mg at bedtime | 0.2-0.4 mg at bedtime | 0.4 mg at bedtime | Oral tablets; take 1 hour before bed |
| Nocturia (nocturnal polyuria) | 0.1 mg at bedtime | 0.1-0.4 mg at bedtime | 0.4 mg at bedtime | Oral tablets; 1 hour before bed |
| Nocturia (oral lyophilisate) | Women: 25 mcg; Men: 50 mcg | 25-50 mcg (women); 50-100 mcg (men) | See SmPC | Place under tongue at bedtime |
Children
Central Diabetes Insipidus (all ages)
Initial dose: 0.1 mg one to two times daily. Titrate based on urine output and thirst. The dose is adjusted individually to achieve adequate control of polyuria and polydipsia while maintaining normal serum sodium. Children require close monitoring and regular sodium level assessments.
Primary Nocturnal Enuresis (aged 5 years and older)
Starting dose: 0.2 mg at bedtime. If insufficient response after 1-2 weeks, the dose may be increased to 0.4 mg. Treatment should be reassessed after 3 months with a structured withdrawal period (at least 1 week without treatment) to assess whether the child still requires medication. Fluid intake must be restricted from 1 hour before to 8 hours after dosing.
Elderly Patients
Elderly patients (65 years and older) require special consideration when starting desmopressin therapy. Age-related decline in renal function, reduced total body water, and alterations in sodium homeostasis make older adults particularly vulnerable to hyponatraemia. The following guidance applies:
- Desmopressin is not recommended for the treatment of nocturia in patients over 65 years unless the benefit clearly outweighs the risk, as this population has the highest rates of severe hyponatraemia
- For diabetes insipidus, start at the lowest effective dose and titrate slowly
- Serum sodium must be measured before starting treatment, after 3 days, after 1 week, after 1 month, and then at regular intervals thereafter
- Any symptoms suggesting hyponatraemia (headache, nausea, confusion, weight gain) must prompt immediate sodium measurement and consideration of dose reduction or discontinuation
Missed Dose
If you miss a dose of desmopressin, take it as soon as you remember. However, if it is close to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Never take a double dose to compensate for a missed one, as this significantly increases the risk of water intoxication and hyponatraemia. If you are taking desmopressin for nocturnal enuresis and miss the bedtime dose, do not take it during the night or the following morning.
Overdose
An overdose of desmopressin leads to a prolonged duration of action with an increased risk of severe hyponatraemia and water retention. Symptoms of overdose may include:
- Headache, nausea, vomiting
- Weight gain and oedema
- Decreased urine output
- Muscle cramps
- Confusion, drowsiness
- In severe cases: seizures, loss of consciousness, cerebral oedema
If you suspect a desmopressin overdose, seek immediate medical attention or contact your local poison control centre. Treatment involves stopping desmopressin, restricting fluid intake, and in severe cases, careful administration of hypertonic saline under intensive care monitoring. Do not attempt to treat severe hyponatraemia at home.
What Are the Side Effects of Desmopressin Teva B.V.?
The most common side effects of desmopressin include headache, nausea, abdominal pain and dizziness. The most serious adverse effect is hyponatraemia (low blood sodium), which can be life-threatening. Side effects are generally dose-related and can be minimised by adhering to fluid restriction guidelines.
Like all medicines, desmopressin can cause side effects, although not everybody experiences them. The frequency and severity of side effects are closely related to the dose used and, importantly, to the patient's adherence to fluid restriction guidelines. Understanding the potential side effects helps you recognise problems early and seek appropriate medical attention when needed.
Very Common (affects more than 1 in 10 people)
- Headache
Common (affects 1 to 10 in 100 people)
- Nausea
- Abdominal pain
- Dizziness
- Dry mouth
- Hyponatraemia (with or without symptoms)
- Peripheral oedema (swelling)
- Fatigue
Uncommon (affects 1 to 10 in 1,000 people)
- Insomnia
- Drowsiness
- Paraesthesia (tingling)
- Visual disturbances
- Palpitations
- Orthostatic hypotension
- Dyspepsia (indigestion)
- Vomiting
- Diarrhoea
- Muscle cramps
- Weight gain
Rare (affects fewer than 1 in 1,000 people)
- Allergic reactions (rash, urticaria, anaphylaxis)
- Severe hyponatraemia with seizures
- Cerebral oedema (extremely rare, related to severe hyponatraemia)
- Coma (in cases of untreated severe hyponatraemia)
- Emotional disturbances in children
The risk of hyponatraemia-related side effects increases significantly when patients fail to restrict their fluid intake appropriately. Symptoms of early hyponatraemia include a persistent headache, nausea, unexplained weight gain, and a general feeling of being unwell. If you experience any of these symptoms, you should stop taking desmopressin and contact your healthcare provider immediately for a sodium level check.
Contact your doctor or go to the emergency department immediately if you experience: severe headache that does not respond to simple painkillers, persistent vomiting, confusion or disorientation, seizures, or sudden significant weight gain. These may be signs of severe hyponatraemia, which requires urgent hospital treatment.
How Should You Store Desmopressin Teva B.V.?
Store desmopressin tablets below 25°C in the original packaging to protect from moisture and light. Oral lyophilisates should be kept in the blister pack until use. Keep all medicines out of reach of children.
Proper storage of desmopressin is important to maintain its effectiveness throughout the shelf life. The active substance can degrade if exposed to excessive heat, moisture or light. Follow these storage guidelines to ensure your medication remains effective:
- Tablets: Store below 25°C (77°F) in the original blister packaging. Do not remove tablets from the blister until ready to take. Protect from moisture
- Oral lyophilisates: Store below 25°C in the original blister packaging. The lyophilisates are sensitive to moisture, so only open the blister immediately before use. Handle with dry hands
- Nasal spray: Store below 25°C. After first opening, the nasal spray solution typically has a shelf life of 4 weeks. Do not freeze
- Injection solution: Store in a refrigerator (2-8°C). Do not freeze. Protect from light
Do not use Desmopressin Teva B.V. after the expiry date printed on the packaging. The expiry date refers to the last day of that month. Do not dispose of medicines in household waste or wastewater. Ask your pharmacist about appropriate disposal methods to help protect the environment.
What Does Desmopressin Teva B.V. Contain?
The active substance is desmopressin acetate, a synthetic nonapeptide analogue of vasopressin. Inactive ingredients (excipients) vary by formulation and may include lactose monohydrate, potato starch, povidone and magnesium stearate in the tablet form.
Each formulation of Desmopressin Teva B.V. contains the active substance desmopressin in the form of desmopressin acetate. Desmopressin is a synthetic nonapeptide (nine amino acid) analogue of the natural posterior pituitary hormone arginine vasopressin (AVP). The structural modification involves deamination of the cysteine at position 1 and substitution of L-arginine with D-arginine at position 8, which enhances V2-receptor selectivity, prolongs the duration of action, and reduces pressor (blood vessel constricting) activity.
Tablet formulation (typical excipients):
- Lactose monohydrate
- Potato starch
- Povidone K30
- Magnesium stearate
Oral lyophilisate formulation (typical excipients):
- Gelatin
- Mannitol
- Citric acid anhydrous
Patients with known lactose intolerance should be aware that the tablet formulation contains lactose monohydrate. Consult your pharmacist or prescribing physician if you have known allergies or intolerances to any excipients. The oral lyophilisate formulation does not contain lactose and may be a suitable alternative.
Frequently Asked Questions about Desmopressin Teva B.V.
Desmopressin is primarily used to treat central diabetes insipidus (a condition where the body cannot produce enough antidiuretic hormone), primary nocturnal enuresis (bedwetting) in children aged 5 and older and adults, and nocturia (excessive nighttime urination) caused by nocturnal polyuria in adults. It works by mimicking the natural hormone vasopressin to help the kidneys retain water and produce less urine. It is also used diagnostically to test how well the kidneys can concentrate urine.
Yes, hyponatraemia (dangerously low blood sodium) is the most serious risk associated with desmopressin. It occurs when excessive water retention dilutes the sodium in your blood. To minimise this risk, you must restrict your fluid intake from 1 hour before taking desmopressin until at least 8 hours afterwards. Your doctor will monitor your sodium levels, especially when starting treatment and after dose adjustments. Early signs include headache, nausea, and weight gain. If you experience these symptoms, stop taking desmopressin and contact your doctor immediately.
Yes, desmopressin is approved for children. For central diabetes insipidus, it can be used from infancy under specialist supervision. For primary nocturnal enuresis (bedwetting), it is approved for children aged 5 years and older who have not responded adequately to non-pharmacological measures such as alarm therapy and fluid management. Children's doses are carefully adjusted by the physician, and strict fluid restriction is essential to prevent hyponatraemia. Treatment should be reassessed after 3 months with a trial off medication.
The onset of action depends on the formulation. Oral tablets typically begin working within 1 hour, with peak antidiuretic effect at approximately 2-4 hours. Oral lyophilisates (melt-on-tongue tablets) have a similar onset. The nasal spray formulation works faster, usually within 15-30 minutes. The duration of the antidiuretic effect is typically 6-14 hours depending on the dose and individual patient response, which is why evening dosing is effective for bedwetting and nocturia.
You should significantly minimise your fluid intake from 1 hour before taking desmopressin until at least 8 hours afterwards. During this period, drink only when you are truly thirsty and limit yourself to small sips. Excessive fluid intake while on desmopressin can lead to dangerous water retention and hyponatraemia (low blood sodium). Your doctor will provide specific guidance on how much fluid is safe to consume. For daytime doses (e.g. for diabetes insipidus), moderate fluid intake is usually acceptable but should still be monitored.
Limited clinical data from pregnant women with diabetes insipidus suggest that desmopressin does not cause significant harm during pregnancy. However, it should only be used when the potential benefit justifies the potential risk to the foetus. Pregnancy can alter fluid balance and sodium homeostasis, so pregnant women taking desmopressin require close monitoring. Animal studies have not shown reproductive toxicity. If you are pregnant or planning to become pregnant, discuss your treatment with your doctor to determine the most appropriate approach.
If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Never take a double dose to make up for a missed one, as this significantly increases the risk of water intoxication and dangerously low sodium levels. If you miss a bedtime dose for enuresis, do not take it in the middle of the night or the following morning. If you frequently forget doses, speak with your doctor about strategies to help you remember.
References
This article is based on the following peer-reviewed sources and authoritative medical references:
- European Medicines Agency (EMA). Desmopressin - Summary of Product Characteristics (SmPC). EMA/CHMP. Accessed January 2026.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List (2023). Geneva: World Health Organization; 2023.
- Vande Walle J, Stockner M, Raes A, et al. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2007;2(3):232-238. doi:10.2174/157488607781668891
- Wesche D, Deen PM, Knoers NV. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr Nephrol. 2012;27(12):2183-2204. doi:10.1007/s00467-012-2118-8
- Glazener CM, Evans JH, Peto RE. Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev. 2005;(2):CD002911. doi:10.1002/14651858.CD002911.pub2
- Rittig S, Knudsen UB, Norgaard JP, et al. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256(4 Pt 2):F664-F671.
- Juul KV, Bichet DG, Nielsen S, Norgaard JP. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am J Physiol Renal Physiol. 2014;306(9):F931-F940. doi:10.1152/ajprenal.00604.2013
- National Institute for Health and Care Excellence (NICE). Nocturnal enuresis: the management of bedwetting in children and young people. Clinical guideline CG111. 2010 (updated 2023).
- British National Formulary (BNF). Desmopressin. NICE Evidence Services. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). Desmopressin Acetate - Prescribing Information. FDA Drug Labels. Accessed January 2026.
Editorial Team
This article was written, reviewed and fact-checked by the iMedic Medical Editorial Team, comprising specialist physicians with expertise in pharmacology, endocrinology and internal medicine.
Medical Writing
iMedic Medical Editorial Team
Specialists in pharmacology and clinical medicine
Medical Review
iMedic Medical Review Board
Independent review following WHO, EMA and FDA guidelines
Evidence Standards
Evidence Level 1A
Based on systematic reviews and meta-analyses
Conflict of Interest
None declared
No commercial funding or pharmaceutical sponsorship